Dietary long-chain omega-3 fatty acids of marine origin: a comparison of their protective effects on coronary heart disease and breast cancers.

The relationship between high fish consumption and low mortality following coronary heart disease (CHD) and low incidence of breast cancer was first mentioned 3 decades ago. The fishes of interest are rich in omega-3 long-chain polyunsaturated fatty acids (omega-3 LC-PUFAs), especially eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), which could be the active nutrients. The current consensus about cardioprotection is that omega-3 LC-PUFAs would mainly exert antiarrhythmic effects. One of the proposed mechanisms is that circulating non-esterified LC-PUFAs partition into cardiac cells membrane phospholipids and exert a direct effect on ionic channels and/or modify intracellular calcium homeostasis. In another hypothesis, changes in the metabolism of phosphoinositides would be involved and lead to the differential activation of PKC isoforms. As compared to the mechanisms proposed for the cardioprotective effects of omega-3 LC-PUFAs, less is known about the molecular mechanisms involved in breast cancers prevention. Some proposed mechanisms such as the modulation of phosphoinositides metabolism and/or modulation of intracellular calcium homeostasis, are common to both pathologies. Other hypotheses involve the alteration of the cellular redox status induced by highly peroxidizable polyunsaturated fatty acids (FA), or the modulation of gene expression, both phenomena being tightly linked to apoptosis. In this review, we report and compare some proposed mechanisms for the involvement of omega-3 LC-PUFAs in both cardiac and breast cancer protection. Deliberately, we chose to discuss only the mechanisms, which are less described in other reviews such as ionic channels in cancer, calcium homeostasis, PKC activation or matrix metalloproteinases in both cancer and cardiac models. The leitmotiv along this review is that cardio- and cancero-protective effects use common pathways. Comparison of the cellular effects might therefore help to highlight the "protective" pathways

Dihydropyridines et systeme nerveux central : participation au controle central de la pression arterielle chez le rat spontanement hypertendu

SIGLECNRS T Bordereau / INIST-CNRS - Institut de l'Information Scientifique et TechniqueFRFranc

raw data 15 herg blocking drugs v2.0 july 2022

This database reports the effects of 15 torsadogenic hERG blocking drugs (astemizole, chlorpromazine, cisapride, droperidol, ibutilide, dofetilide, haloperidol, moxifloxacin, pimozide, quinidine, risperidone, sotalol, sertindole, terfenadine, thioridazine)  assessed by telemetry in beagle dogs. Hemodynamic effects on diastolic and systolic arterial pressure were analysed from the first doses causing QTc prolongation and/or HFQT oscillations enhancement. Autonomic control changes were analysed with the High Frequency Autonomic Modulation (HFAM) model. When compared to to the previous version (march 2022), this new version (v2.0) includes hemodynamic effects on stroke volume, cardiac output and systemic vascular resistances. The latter parameters were modelled using pulse contour analysis of the blood pressure telemetry. signal </p

ERBC telemetry database 24 drug V2.2

This new version of the ERBC telemetry database includes analysis of telemetry data for 24 drugs including 15 torsadogenic drugs This database reports  drug-induced cardiovascular effects on blood pressure (abdominal aortic pressure), heart rate, QT and QTc interval, PQ interval. It also includes modelling data of haemodynamic effects on central aortic pressure, stroke volume, cardiac output and systemic vascular resistances (AUCsys model) and modelling of effects on the autonomic nervous system (HFAM model).</p

ERBC telemetry database 24 drugs v2.4

This new version of the ERBC telemetry database includes analysis of telemetry data for 24 drugs including 15 torsadogenic drugs This database reports drug-induced cardiovascular effects on blood pressure (abdominal aortic pressure), heart rate, QT and QTc interval, PQ interval. It includes results of in silico modelling (iSV model) of haemodynamic effects on central aortic pressure, stroke volume, cardiac output and systemic vascular resistance and in silico modelling of effects on the autonomic nervous system (HFAM model).</p

ERBC telemetry database 24 drugs V2.3

 This new version of the ERBC telemetry database includes analysis of telemetry data for 24 drugs including 15 torsadogenic drugs This database reports  drug-induced cardiovascular effects on blood pressure (abdominal aortic pressure), heart rate, QT and QTc interval, PQ interval. It also includes modelling data of haemodynamic effects on central aortic pressure, stroke volume, cardiac output and systemic vascular resistances (AUCsys model) and modelling of effects on the autonomic nervous system (HFAM model). Compared to V2.2, this new version V2.3 includes drugs effects on abdominal and central aortic pressure. </p

raw data 15 herg blocking drugs march 2022

Effects of 15 torsadogenic hERG blocking drugs (astemizole, chlorpromazine, cisapride, droperidol, ibutilide, dofetilide, haloperidol, moxifloxacin, pimozide, quinidine, risperidone, sotalol, sertindole, terfenadine, thioridazine) were assessed by telemetry in beagle dogs. Hemodynamic effects on diastolic and systolic arterial pressure were analysed from the first doses causing QTc prolongation and/or HFQT oscillations enhancement. Autonomic control changes were analysed with the High Frequency Autonomic Modulation (HFAM) model

Raw data 22 reference compounds by telemetry

The version V2.1 is the last update of raw data of the ERBC telemetry database in beagle dogs This new version is is accrued from 22 reference compounds including 15 herg blockers. The list of reference drugs is: astemizole, atenolol, atropine,  chlorpromazine, cisapride, droperidol, ibutilide, dofetilide, haloperidol, hexamethonium, isoprenaline, moxifloxacin, nicardipine, pimozide, prazosin, quinidine, risperidone, sotalol, sertindole, terfenadine, thioridazine, verapamil. When compared to the 2.0 version, the 2.1 version includes new analysis by PCA of haemodynamic parameters for 3 additionnal drugs: isoprenaline, prazosin and verapamil.</p